Scientists Find How Bacteria In Cows' Milk May Cause Crohn's Disease

Scientists at the University of Liverpool have found how a bacterium, known to cause illness in cattle, may cause Crohn's disease in humans. Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea.

Intestinal Inflammation Decreased By Il-22 Gene

There are two major types of inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative colitis (UC). Conflicting reports have indicated that the soluble factor IL-22 can have both IBD promoting and IBD controlling effects. But now, Atsushi Mizoguchi and colleagues at Massachusetts General Hospital, Boston, have established that IL-22 ameliorates disease in a mouse model of UC.

FDA Approves Tysabri To Treat Moderate-To-Severe Crohn's Disease

The U.S. Food and Drug Administration has approved Tysabri (natalizumab) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies.

FDA Approves Tysabri reg; For The Treatment Of Moderate-To-Severe Crohn's Disease

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) for TYSABRI (natalizumab).

Asacol 800mg MR Tablets Dosed At 4.8g Day Herald Fast Symptom Relief And Improved Quality Of Life For Moderately Active UC Patients

Procter & Gamble Pharmaceuticals (NYSE: P&G) announced that Asacol(R) (mesalazine) 800mg Modified Release (MR) tablets are now available in the UK for the treatment of mild to moderate acute exacerbations of ulcerative colitis (UC), and the maintenance of remission in UC and Crohn's ileo-colitis patients.

Improved Treatment For Crohn's Disease

An international research study, published in The Lancet, has thrown into question the current method of treating Crohn's disease - opening the door to a safer and more effective treatment option for sufferers of the chronic disease."Our study clearly demonstrated that this alternative treatment method was more effective at inducing disease remission than the conventional method, " said Dr.

Inflammatory Bowel Disease May Mimic Gynecological Disorders In Its Clinical Presentation

Endometriosis is a condition of unknown etiology in which endometrial tissue occurs at extra-uterine sites, including ovaries, fallopian tubes, and gastrointestinal tract. It usually occurs between 30 and 40 years of age. Four to 17% of menstruating women develop endometriosis.

New Treatment Strategy For Crohn's Disease Shows Promise

When treating patients with Crohn's disease, early use of an intensivecombined immunosuppression (CI) in combination withconventional management is more effective than the current standard, treatment with corticosteroids. These outcomes were reported in anArticle in the February 23, 2008 issue of The Lancet.

Early Data On Cimzia reg; Shows Promise In Crohn's Patients Without Infliximab

Datafrom the WELCOME trial presented at the third congress of the EuropeanCrohn's and Colitis Organisation (ECCO) show that, at the six weekmark, Cimzia (certolizumab pegol) is effective in Crohn's patientsshowing intolerance or no response to infliximab.

Caspase-12: MUHC Researcher Finds New Defense Mechanism Against Intestinal Inflammation

The body's first line of defence against pathogenic bacteria that we ingest may not be the immune system but rather the cells that line the intestine. This surprising conclusion is just one facet of a study by Dr. Maya Saleh, a researcher at the Research institute of the McGill University Health Centre, published in the journal Cell Host & Microbe on March 12.